U.S. And Europe Invasive BCI Market Trend Report: From Clinical Trials To Commercial Access, 2025 - 2033

Table of Contents

Chapter 1 Competitive Intelligence
                   1.1 Competitive Landscape: Introduction
                   1.2 Scope, Universe and Evidence Framework
                       1.2.1 Company Universe and Classification
                       1.2.2 Source Hierarchy and Evidence Standard
                       1.2.3 Company / Competition Categorisation
                       1.2.4 Definitional Boundary and Commercial Precedent
                   1.3 Company Market Position Analysis, 2025
                       1.3.1 Methodology: Basis of Measurement
                       1.3.2 Installed Base Share
                       1.3.3 Capital Share and Funding Position
                       1.3.4 Positioning Matrix and Key Takeaways
                   1.4 Company Profiles
                       1.4.1 Neuralink
                       1.4.2 Synchron, Inc.
                       1.4.3 Precision Neuroscience Corporation
                       1.4.4 Paradromics, Inc.
                       1.4.5 Blackrock Neurotech
                       1.4.6 Science Corporation
                       1.4.7 ONWARD Medical N.V.
                       1.4.8 CorTec GmbH
                       1.4.9 INBRAIN Neuroelectronics
                       1.4.10 ABILITY Neurotech
                       1.4.11 Neurosoft Bioelectronics
                       1.4.12 Echo Neurotechnologies
                       1.4.13 Merge Labs: Adjacent Watchlist
                       1.4.14 Neuracle: Ex-Region Benchmark
                   1.5 Cross-Company Benchmarking
                       1.5.1 Product / Technology Benchmarking
                       1.5.2 Technology Benchmarking Dimensions
                       1.5.3 Clinical Evidence Benchmarking
                       1.5.4 Regulatory Pathway Benchmarking
                   1.6 Reimbursement and Market Access
                   1.7 Strategy Mapping
                       1.7.1 New Product and Technology Launches
                       1.7.2 Partnerships and Collaborations
                       1.7.3 Funding and Investment
                       1.7.4 Clinical and Regulatory Milestones
                       1.7.5 Mergers and Acquisitions
                   1.8 Strategic Acquirer and Channel Landscape
                   1.9 Methodology
Chapter 2 Market Sizing: TAM / SAM / SOM
                   2.1 Executive Summary
                   2.2 Scope and Definitional Boundary
                   2.3 Application Segmentation: The Complete Invasive BCI Market
                   2.4 Model Architecture: How TAM, SAM and SOM Are Built
                   2.5 Epidemiology and Clinically Addressable Population
                   2.6 Total Addressable Market (TAM), 2021 - 2033
                   2.7 Serviceable Addressable Market (SAM): The Regulatory and Reimbursement Gates
                   2.8 Serviceable Obtainable Market (SOM): Capacity Is the Binding Constraint
                   2.9 Segment Breakdown: Application and Modality
                   2.10 Geographic Breakdown: U.S. and Eight Notable European Markets
                   2.11 Company-Level SOM Allocation
                   2.12 Non-Medical Applications: Commercial Viability Assessment
                   2.13 Scenario Range: Low / Base / High
Chapter 3 Investment Thesis
                   3.1 Executive Summary: The Investment View
                   3.2 Investment Framework and Scoring Basis
                   3.3 Investment Opportunity Ranking
                   3.4 Value at Stake: Modelled Revenue Position by Company
                   3.5 Capital Efficiency: What Each Company Is Priced Against
                   3.6 Value Inflection Points and Catalyst Calendar
                   3.7 Investment Risk Framework
                   3.8 Company-Level Investment Thesis
                       3.8.1 Attractive Opportunities
                       3.8.2 Selective and Speculative
                   3.9 Watch List: Ex-Region and Adjacent Modality
                   3.10 Exit Scenarios and Acquirer Landscape
                   3.11 Investor Prioritization by Mandate
                   3.12 Methodology